BeOne Medicines (ONC) Amortizatization of Intangibles (2018 - 2019)
BeOne Medicines' (ONC) quarterly Amortizatization of Intangibles came in at -$51000.0 in Q3 2019, up 98.85% year-over-year from -$25647.3 in Q3 2018, and up 95.9% quarter-over-quarter from -$1.2 million in Q2 2019.
Powered by 
Analysis
BeOne Medicines (ONC) Amortizatization of Intangibles (2018 - 2019) Analysis & Trends
BeOne Medicines (ONC) has reported Amortizatization of Intangibles for 2 consecutive years, with -$51000.0 the latest figure, recorded in Q3 2019.
- On a quarterly basis, Amortizatization of Intangibles rose 98.85% year-over-year to -$51000.0 in Q3 2019; TTM through Sep 2019 was -$7.3 million, a 64.29% decrease from a year earlier, with the FY2018 full-year figure at -$8.0 million, changed N/A from the prior year.
- Amortizatization of Intangibles was -$51000.0 for Q3 2019 at BeOne Medicines, up from -$1.2 million in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at -$51000.0 in Q3 2019 and troughed at -$4.4 million in Q3 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | 984.00 Mn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | - |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | 4.33 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2019 | -51,000.00 |
| Jun 30, 2019 | -1.24 Mn |
| Mar 31, 2019 | -2.41 Mn |
| Dec 31, 2018 | -3.59 Mn |
| Sep 30, 2018 | -4.44 Mn |